COVID19: FDA approves convalescence plasma treatment

The Food and Drugs Authority (FDA) has given approval to an investigational convalescent plasma collected from individuals who have recovered from COVID-19 for the treatment of critically ill COVID-19 patients.

Convalescent plasma (CP) is the term used for plasma that is removed from the blood of a person who has recovered from a disease, then transfused into a patient still battling it.

According to the Presidential Advisor on Health, Dr Anthony Nsiah-Asare, the approval was given on Monday, June 15.

It is expected that CP would be given to patients with severe COVID-19 to boost their ability to fight the virus.

It is also expected to help keep people who are moderately ill from becoming more ill and experiencing COVID-19 complications.


You might also like

Comments are closed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

%d bloggers like this: